Thioredoxin-1 protects against androgen receptor-induced redox vulnerability in castration-resistant prostate cancer

Androgen deprivation (AD) therapy failure leads to terminal and incurable castration-resistant prostate cancer (CRPC). We show that the redox-protective protein thioredoxin-1 (TRX1) increases with prostate cancer progression and in androgen-deprived CRPC cells, suggesting that CRPC possesses an enha...

Descripción completa

Detalles Bibliográficos
Autores principales: Samaranayake, Govindi J., Troccoli, Clara I., Huynh, Mai, Lyles, Rolando D. Z., Kage, Karen, Win, Andrew, Lakshmanan, Vishalakshi, Kwon, Deukwoo, Ban, Yuguang, Chen, Steven Xi, Zarco, Enrique Rodriguez, Jorda, Merce, Burnstein, Kerry L., Rai, Priyamvada
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5663934/
https://www.ncbi.nlm.nih.gov/pubmed/29089489
http://dx.doi.org/10.1038/s41467-017-01269-x

Ejemplares similares

Ejemplares similares